CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
EBV 特异性细胞毒性 T 淋巴细胞治疗实体器官移植受者难治性 EBV 相关移植后淋巴增殖性疾病：一项系统评价
英文原题：EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
查看英文原题
EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在造血干细胞移植（HSCT）后发生移植后淋巴增殖性疾病（PTLD）的患者中，使用EB病毒特异性细胞毒性T淋巴细胞（EBV-CTLs）进行过继免疫治疗已显示出安全性和有效性。EBV-CTLs也可能成为实体器官移植（SOT）受者难治性PTLD的有效治疗方法。两名独立评估者检索了Pubmed、Embase、Cochrane Library和Web of Science从建库至2020年11月的文献。共纳入11项研究，涉及76例患者（42例，55%为男性）。
我们提取了数据并完成了质量评估。大多数研究来自欧洲和美国。肝移植和肾移植占移植类型的大多数。35例（46.1%）患者被诊断为单形性PTLD，其中B淋巴细胞型最为常见。所有患者均接受了PTLD的一线治疗，但治疗无效。CTLs包括自体EBV-CTLs（15/76，22%）和HLA匹配的第三方EBV-CTLs（61/76，78%）。EBV-CTL治疗难治性PTLD的缓解率为66%。在50例患者中，36例达到完全缓解，14例达到部分缓解。39例患者EBV-DNA水平下降。不良反应罕见且轻微。
我们得出结论，EBV特异性CTLs过继治疗在PTLD中是安全、耐受性良好且有效的。
展开英文摘要原文
The use of Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) in adoptive immunotherapy in hematopoietic stem cell transplantation (HSCT) patients with post-transplantation lymphoproliferative disorder (PTLD) has demonstrated safety and effectiveness.
EBV-CTLs might also be the effective treatment of refractory PTLD of solid organ transplantation (SOT) recipients. Two independent assessors searched Pubmed, Embase, Cochrane Library, and Web of Science from their inception to November 2020. Eleven studies with 76 patients (42, 55% male) were included.
We extracted the data and completed the quality assessments. Most of the studies were from Europe and the USA. Liver and kidney transplantation accounted for most of the transplant types. Thirty-five (46. 1%) patients were diagnosed with monomorphic PTLD, and B lymphocyte type was the most common. All the patients received primary treatment for PTLD while it was ineffective.
CTLs included autologous EBV-CTLs (15/76, 22%) and HLA-matched third-party EBV-CTLs (61/76, 78%). The response rate for EBV-CTL treatment of refractory PTLD was 66%. Of 50 patients, 36 achieved complete remission and 14 achieved partial remission. EBV-DNA level decreased in 39 patients. Adverse reactions were rare and mild.
We conclude that adoptive therapy with EBV-specific CTLs is safe, well-tolerated, and effective in PTLD.
论文信息
- 作者
- Liu JY、Zhang JM、Zhan HS、Sun LY、Wei L
- 单位
- Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.China
- 文献类型
- 系统综述
- 期刊
- Transplant international : official journal of the European Society for Organ Transplantation2021 Dec
- 原文标识
- PubMed 34510581 · DOI 10.1111/tri.14107